Neumora Therapeutics, Inc.

The momentum for this stock is not very good. Neumora Therapeutics, Inc. is not a good value stock. Neumora Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Neumora Therapeutics, Inc..

News

Buy Rating Affirmed for Neumora Therapeutics Amid Strong Progress in Depression and CNS Disorder Treatments

TipRanks Financial Blog Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on NMRA stock, giving a Buy rating on September 4. Graig Suvannavej...\n more…

RBC Capital Reaffirms Their Buy Rating on Neumora Therapeutics, Inc. (NMRA)

TipRanks Financial Blog In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Neumora Therapeutics, Inc. (NMRA - Research Report), with a ...\n more…

Reviewing Neumora Therapeutics (NASDAQ:NMRA) & Kyverna Therapeutics (NASDAQ:KYTX)

Ticker Report Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) and Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast...\n more…

Neumora Therapeutics (NASDAQ:NMRA) Trading 2.6% Higher

Zolmax Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report)'s share price was up 2.6% during mid-day trading on Wednesday . The stock traded as high as $11.86 and last traded at $11.86. Approximately...\n more…

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Zolmax Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine brokerages that are currently covering the stock...\n more…

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Moderate Buy" from Analysts

Ticker Report Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have been given an average rating of "Moderate Buy" by the nine analysts that are covering the company, MarketBeat.com reports...\n more…